A behavioural model to reveal place preference to Δ9-tetrahydrocannabinol in mice

被引:161
作者
Valjent, E
Maldonado, R [1 ]
机构
[1] Univ Pompeu Fabra, Lab Neurofarmacol, Fac Ciencies Salut & Vida, E-08003 Barcelona, Spain
[2] Univ Paris 06, Lab Neurochim Anat, Inst Neurosci, UMR 7624,CNRS, F-75005 Paris, France
关键词
Delta; 9-tetrahydrocannabinol; mouse; reward; place preference; SR; 141716A;
D O I
10.1007/s002130050013
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: The rewarding properties of Delta 9-tetrahydrocannabinol (THC) are difficult to demonstrate in rodents using standard procedures. Objective: To evaluate the motivational responses of THC in the place conditioning paradigm in mice after minimizing the dysphoric effects of the first drug exposure and/or the consequences of its pharmacokinetic properties. Methods: Mice were conditioned to THC (1 or 5 mg/kg) using an unbiased procedure with an elevated number of pairings and long conditioning time. Results: A place aversion was observed with 5 mgflcg THC using a standard pl otocol. Similar results were obtained when the CB-1 receptor antagonist SR 131716A (1 mg/kg) was administered immediately after each THC conditioning period. However, mice receiving a priming THC injection and conditioned 24 h later showed a place preference with 1 mg/kg THC and no effect with 5 mg/kg THC, Conclusion: THC produces a clear place preference in mice by using a long period of conditioning and avoiding the possible dysphoric consequences of the first drug exposure.
引用
收藏
页码:436 / 438
页数:3
相关论文
共 21 条
[1]  
Adams IB, 1996, ADDICTION, V91, P1585, DOI 10.1111/j.1360-0443.1996.tb02264.x
[2]   CONFORMATIONALLY RESTRAINED ANALOGS OF PRAVADOLINE - NANOMOLAR POTENT, ENANTIOSELECTIVE, (AMINOALKYL)INDOLE AGONISTS OF THE CANNABINOID RECEPTOR [J].
DAMBRA, TE ;
ESTEP, KG ;
BELL, MR ;
EISSENSTAT, MA ;
JOSEF, KA ;
WARD, SJ ;
HAYCOCK, DA ;
BAIZMAN, ER ;
CASIANO, FM ;
BEGLIN, NC ;
CHIPPARI, SM ;
GREGO, JD ;
KULLNIG, RK ;
DALEY, GT .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (01) :124-135
[3]   Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal [J].
deFonseca, FR ;
Carrera, MRA ;
Navarro, M ;
Koob, GF ;
Weiss, F .
SCIENCE, 1997, 276 (5321) :2050-2054
[4]  
DEVANE WA, 1988, MOL PHARMACOL, V34, P605
[5]  
DICHIARA G, 1991, MESOLIMBIC DOPAMINE, P331
[6]  
ELDRIDGE JC, 1992, MARIJUANA CANNABINOI, P93
[7]   Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra [J].
French, ED ;
Dillon, K ;
Wu, XF .
NEUROREPORT, 1997, 8 (03) :649-652
[8]   Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors [J].
Gessa, G ;
Melis, M ;
Muntoni, A ;
Diana, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 341 (01) :39-44
[9]   Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Δ-9-tetrahydrocannabinol [J].
Hutcheson, DM ;
Tzavara, ET ;
Smadja, C ;
Valjent, E ;
Roques, BP ;
Hanoune, J ;
Maldonado, R .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (07) :1567-1577
[10]   FAILURE TO OBTAIN CANNABIS-DIRECTED BEHAVIOR AND ABSTINENCE SYNDROME IN RATS CHRONICALLY TREATED WITH CANNABIS-SATIVA EXTRACTS [J].
LEITE, JR ;
CARLINI, EA .
PSYCHOPHARMACOLOGIA, 1974, 36 (02) :133-145